210 related articles for article (PubMed ID: 29042609)
1. Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.
Bogusz J; Zrubek K; Rembacz KP; Grudnik P; Golik P; Romanowska M; Wladyka B; Dubin G
Sci Rep; 2017 Oct; 7(1):13399. PubMed ID: 29042609
[TBL] [Abstract][Full Text] [Related]
2. Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
Parker LJ; Taruya S; Tsuganezawa K; Ogawa N; Mikuni J; Honda K; Tomabechi Y; Handa N; Shirouzu M; Yokoyama S; Tanaka A
Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):392-404. PubMed ID: 24531473
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of pim1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode.
Lee SJ; Han BG; Cho JW; Choi JS; Lee J; Song HJ; Koh JS; Lee BI
PLoS One; 2013; 8(7):e70358. PubMed ID: 23936194
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.
Holder S; Zemskova M; Zhang C; Tabrizizad M; Bremer R; Neidigh JW; Lilly MB
Mol Cancer Ther; 2007 Jan; 6(1):163-72. PubMed ID: 17218638
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko A; Zhang L; Le Brazidec JY; Fan J; Chong JH; Hingway A; Raditsis A; Singh L; Elenbaas B; Hong VS; Marcotte D; Silvian L; Enyedy I; Chao J
Bioorg Med Chem Lett; 2015 Feb; 25(3):474-80. PubMed ID: 25575657
[TBL] [Abstract][Full Text] [Related]
7. 3D QSAR studies, molecular docking and ADMET evaluation, using thiazolidine derivatives as template to obtain new inhibitors of PIM1 kinase.
Aouidate A; Ghaleb A; Ghamali M; Ousaa A; Choukrad M; Sbai A; Bouachrine M; Lakhlifi T
Comput Biol Chem; 2018 Jun; 74():201-211. PubMed ID: 29635214
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
Akué-Gédu R; Rossignol E; Azzaro S; Knapp S; Filippakopoulos P; Bullock AN; Bain J; Cohen P; Prudhomme M; Anizon F; Moreau P
J Med Chem; 2009 Oct; 52(20):6369-81. PubMed ID: 19788246
[TBL] [Abstract][Full Text] [Related]
9. Insights from Pim1 structure for anti-cancer drug design.
Ogawa N; Yuki H; Tanaka A
Expert Opin Drug Discov; 2012 Dec; 7(12):1177-92. PubMed ID: 23004574
[TBL] [Abstract][Full Text] [Related]
10. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
11. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
13. Identification of quinones as novel PIM1 kinase inhibitors.
Schroeder RL; Goyal N; Bratton M; Townley I; Pham NA; Tram P; Stone T; Geathers J; Nguyen K; Sridhar J
Bioorg Med Chem Lett; 2016 Jul; 26(13):3187-3191. PubMed ID: 27173800
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
Kumar A; Mandiyan V; Suzuki Y; Zhang C; Rice J; Tsai J; Artis DR; Ibrahim P; Bremer R
J Mol Biol; 2005 Apr; 348(1):183-93. PubMed ID: 15808862
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
16. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
17. Using insights into Pim1 structure to design new anticancer drugs.
Schenone S; Tintori C; Botta M
Curr Pharm Des; 2010; 16(35):3964-78. PubMed ID: 21158732
[TBL] [Abstract][Full Text] [Related]
18. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
19. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
[TBL] [Abstract][Full Text] [Related]
20. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
